Navigation Links
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/19/2007

on day 42.

Study Results

RAV12 was moderately well-tolerated with fractionated dosing that allowed delivery of an "effective dose" (i.e. 1.5 mg/kg total dose over one week time) as 0.75 mg/kg twice weekly. The two primary side effects observed were Infusion-associated abdominal discomfort and diarrhea, and elevated liver function tests. Both side effects appear related to CMax as they tended to appear early on after dosing and tended to resolve rapidly after dosing, and were ameliorated by fractionated dosing.

Treatment with RAV12 demonstrated preliminary evidence of anti-tumor activity. One patient with refractory colorectal cancer experienced a partial remission with time to progression exceeding 8 months and one patient with advanced pancreatic cancer had a > 50% reduction in the relevant tumor marker, CA19-9 and experienced disease stability for more than five months.

As a result of these findings, future development of RAV12 both as single agent and in combination with chemotherapy is planned for 2008. The recommended dose and schedule for Phase 2 clinical study of RAV12 is 0.75 mg/kg twice weekly.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody which is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacio
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 3SBio Inc., ("3SBio") a leading biotechnology ... focusing on researching, developing, manufacturing and marketing biopharmaceutical ... an exclusive license agreement with JenKem Technology Co., ... in Mainland China of PEG-irinotecan, a long-acting polymer-drug ... over-expressed in many solid tumors, including colorectal, ovarian, ...
(Date:9/16/2014)... OAKLAND, Calif. , Sept. 16, 2014  Chairman ... that Richard (Dick) Daniels will assume the ... Foundation Hospitals and Health Plan, Inc., effective immediately. ... developing and implementing technological advancements that advance the high-quality ... members," Tyson said. " Dick Daniels has extensive ...
(Date:9/16/2014)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... all of the outstanding shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: ... $28.10 in a cash and stock transaction valued at $2.2 ... to Auxilium,s closing price on September 16, 2014 and a ... for the previous 30 days.  Under the terms of the ...
Breaking Medicine Technology:3SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer 2Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 2Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 3Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 4Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 5Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 6Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 7
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
(Date:9/17/2014)... In honor of National Health IT Week ... IT professionals for gaining a competitive edge in the ... shows demand for qualified health IT professionals are at ... the differentiating factor when filling a position. The skill ... has clinical workflow and terminology experience. American Sentinel offers ...
(Date:9/17/2014)... CA / MANILA, PHILIPPINES (PRWEB) September 17, 2014 ... providing Managed Operations and Business Process Outsourcing (BPO) services ... joined the firm as the Senior Vice President – ... U.S.. , Cary Weltken is a 15 year ... a wealth of experience in helping companies, ranging in ...
(Date:9/17/2014)... 17, 2014 Health.Verticalize, a healthcare marketing ... their health insurance options in the 2014 open enrollment ... , Moving forward Health Network will be ... company has intentionally remained out of the spotlight for ... a single website to its present position with dozens ...
(Date:9/17/2014)... September 17, 2014 1st-Dress.com, one of ... range of long bridesmaid dresses recently. All ... with top quality materials. Furthermore, they are offered at ... percent off. , The firm is striving to ... More importantly, its workers never compromises on style, quality ...
(Date:9/16/2014)... 2014 Top10BestSEOHosting.com has recently compared ... recommended companies for the webmasters that want to ... , The senior spokesman for Top10BestSEOHosting.com says, ... and HostMonster are the excellent hosting companies for ... a wide range of advanced features while still ...
Breaking Medicine News(10 mins):Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 4Health News:MicroSourcing Appoints New Senior Vice President of North America 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:2014 Long Bridesmaid Dresses Available Online At 1st-Dress.com 2Health News:Top10BestSEOHosting.com: Arvixe Is One Of The Best SEO Hosting Suppliers 2
... DENVER, July 31 Birner Dental Management,Services, Inc. ... dental practices,will conduct a conference call to review ... results, the teleconference may include,discussion of management,s expectations ... be held on Thursday, August 14, 2008 at ...
... 9% Increase In Revenues - - Florida Upholds Contract Award To Orchid ... ... - Regional Tender Work Underway In U.K. -, PRINCETON, N.J., ... identity DNA testing,services, today reported its financial results for the second quarter of,2008., ...
... Fla., July 31 NeoGenomics, Inc.,(OTC Bulletin Board: NGNM) today ... during the quarter included,the following:, Second Quarter 2008 ... 07 -- 17% sequential increase in revenue vs. Q1 ... initiative -- Average number of tests/requisition ...
... safety services, gained four new contracts in the second quarter, including ... awarded a significant contract expansion. , ... Little Falls, ... http://www.sentrx.com/drug_safety_services.shtml [drug safety __title__ drug safety] services, announced today ...
... QHR hospital client King,s Daughters Medical Center (KDMC) in ... grant as a part of the 2009 Health and ... by the Senate Appropriations Committee earlier this month. KDMC,s ... Wicker (Miss.), was initiated by QHR and its strategic ...
... The bestselling guide is now filled with new, essential information for knowing ... treatable disease. , ... Hoboken, NJ (PRWEB) July 31, 2008 -- Ever ... the book has been a major resource for those with diabetes and ...
Cached Medicine News:Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 2Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 3Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 4Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 5Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 6Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 7Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 8Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 9Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 2Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 3Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 4Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 5Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 6Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 7Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 8Health News:Sentrx Growth Continues with Four New Clients in Second Quarter 2Health News:Sentrx Growth Continues with Four New Clients in Second Quarter 3Health News:Healthcare Consulting Leader QHR, Strategic Health Care, Sen. Roger Wicker Partnership Yields $500,000 Grant for King's Daughters Medical Center 2Health News:Healthcare Consulting Leader QHR, Strategic Health Care, Sen. Roger Wicker Partnership Yields $500,000 Grant for King's Daughters Medical Center 3Health News:Diabetes For Dummies, 3rd Edition, Reports on the Latest Developments in the Field 2Health News:Diabetes For Dummies, 3rd Edition, Reports on the Latest Developments in the Field 3Health News:Diabetes For Dummies, 3rd Edition, Reports on the Latest Developments in the Field 4
... These offer truly exceptional quality for this ... aberration has been dramatically improved with performance ... These objectives are also corrected for spherical ... entire 22mm field of view. The DL ...
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark...
... Designed for the scientist who wants ... the TE2000E2 is a high precision Z-focus ... This makes it possible to expand ... sources and image outputs. A five-way ...
... The IX71's modular ... provides 9 access ports ... output devices. Up to ... simultaneous access to a ...
Medicine Products: